Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
PD-L2 (PDCD1LG2) Mouse anti-Human, Clone: UMAB223, liquid, UltraMAB™

Mouse Monoclonal Antibody
Supplier: OriGene UM870115

Description
CD273 (PDCD1 Ligand 2, Programmed cell death 2 ligand 2, PD-L2, B7-DC) is involved in cell-mediated immune responses initiated by T lymphocytes that are stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as CD273 that mediate inhibitory signals from the APC (antigen presenting cell). CD273 can bind two different but related ligands, PDL-1 and PDL-2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PDL-2 can act to stimulate an immunogenic response through and alternative receptor from PD-1. At least three isoforms of PDL-2 are known to exist; CD273 is specific to the largest isoform. Diseases associated with CD273 include cysticercosis, and myasthenic syndrome.Specifications
PD-L2 (PDCD1LG2) | |
Monoclonal | |
0.5-1.0 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
Q9BQ51 | |
PDCD1LG2 | |
Full length human recombit protein of human PDCD1LG2 produced in HEK293T cell. | |
30 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Flow Cytometry, Immunohistochemistry (Paraffin) | |
UMAB223 | |
Unconjugated | |
PDCD1LG2 | |
B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2, bA574F11.2 | |
Mouse | |
Affinity Chromatography | |
RUO | |
80380 | |
-20° C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction